Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis ($NVS) snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal. The Swiss drugmaker isn't saying much about the deal--it won't discuss the potential milestone payments that are part of the deal--but does say it plans to hustle the drug into a Phase IIb study for either diabetic neuropathy or postherpetic neuralgia, otherwise known as shingles pain. More from FierceBiotech

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.